The American Gastroenterological Association's venture capital fund, the GI Opportunity Fund, has invested in single-use endoscopy system developer EvoEndo.
EvoEndo is developing platforms for unsedated transnasal endoscopies. Its single-use endoscopy system received FDA 510(k) clearance in February 2022, according to an April 13 news release from the company.
The EvoEndo system is designed to allow hospitals to move endoscopy procedures from an ambulatory procedural suite to an office-based environment, saving sedation procedure rooms for more complex cases.
Capital for the AGA's venture fund will be provided by venture capital platform Varia Ventures, the release said.